Reactivations of Cytomegalovirus, Human Herpes Virus 6, and Epstein-Barr Virus Differ with Respect to Risk Factors and Clinical Outcome after Hematopoietic Stem Cell Transplantation

2010 ◽  
Vol 42 (8) ◽  
pp. 3273-3276 ◽  
Author(s):  
E. Jaskula ◽  
D. Dlubek ◽  
M. Sedzimirska ◽  
D. Duda ◽  
A. Tarnowska ◽  
...  
Keyword(s):  
Risk Factors ◽  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Epstein Barr Virus ◽  
Human Herpes ◽  
Hematopoietic Stem ◽  
Barr Virus ◽  
Human Herpes Virus ◽  
Human Herpes Virus 6 ◽  
Epstein Barr

scholarly journals Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disorders after Hematopoietic Stem Cell Transplantation: Pathogenesis, Risk Factors and Clinical Outcomes

Cancers ◽  
2020 ◽  
Vol 12 (2) ◽  
pp. 328
Author(s):  
Ayumi Fujimoto ◽  
Ritsuro Suzuki
Keyword(s):  
Risk Factors ◽  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Epstein Barr Virus ◽  
Lymphoproliferative Disorders ◽  
Hematopoietic Stem ◽  
Barr Virus ◽  
Epstein Barr

Epstein-Barr virus (EBV) is a ubiquitous virus belonging to the human γ-herpes virus subfamily. After primary infection, EBV maintains a life-long latent infection. A major concern is that EBV can cause a diverse range of neoplasms and autoimmune diseases. In addition, patients undergoing hematopoietic stem cell transplantation or solid organ transplantation can experience post-transplant lymphoproliferative disorders (PTLDs) due to dysfunction or suppression of host’s immune system, or uncontrolled proliferation of EBV-infected cells. In recent years, the number of EBV-associated PTLD cases has increased. This review focuses on the current understandings of EBV-associated PTLD pathogenesis, as well as the risk factors and clinical outcomes for patients after allogeneic stem cell transplantation.

Sign in / Sign up

Export Citation Format

Share Document